Literature DB >> 9551295

New drugs for epilepsy.

J W Sander1.   

Abstract

Seizure freedom with no side-effects is the aim of treatment, and new antiepileptic drugs have not lived up to expectations; only a few patients with chronic epilepsy have been rendered seizure-free. These treatments have side-effects but their safety profile may be better than older alternatives, although chronic effects have not yet been established. This article reviews newly marketed antiepileptic drugs. It concentrates on shortcomings of current antiepileptic treatment and on the way drugs are developed. A new approach to treatment is long overdue. The development of rational antiepileptic treatments should be strongly encouraged. More clinically relevant paradigms need to be developed and incorporated into clinical trial programmes as these are presently biased in their designs towards regulatory issues.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9551295     DOI: 10.1097/00019052-199804000-00011

Source DB:  PubMed          Journal:  Curr Opin Neurol        ISSN: 1350-7540            Impact factor:   5.710


  2 in total

1.  The anticonvulsant effects of the enantiomers of losigamone.

Authors:  F A Jones; J A Davies
Journal:  Br J Pharmacol       Date:  1999-11       Impact factor: 8.739

2.  Economic evaluation of levetiracetam as an add-on therapy in patients with refractory epilepsy.

Authors:  Lucie Blais; Odile Sheehy; Jean-Marc St-Hilaire; Giles Bernier; Philippe Godfroid; Jacques J LeLorier
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.